<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396513</url>
  </required_header>
  <id_info>
    <org_study_id>1142/05</org_study_id>
    <nct_id>NCT00396513</nct_id>
  </id_info>
  <brief_title>Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.</brief_title>
  <official_title>Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effects of statins (simvastatin) and metformin on
      clinical (menstrual cycle, excessive hair, skin problems), endocrine (androgens), metabolic
      (lipids, markers of systemic inflammation), and endothelial function parameters in women with
      polycystic ovary syndrome (PCOS).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum testosterone</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>regularity of menstrual cycle</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lutropin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum follitropin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum DHEAS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum SHBG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum insulin</measure>
  </secondary_outcome>
  <condition>Polycystic Ovary Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin and Metformin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCO - ESHRE/ASRM criteria:oligomenorrhea (&lt;8 spontaneus menses per year) and
             hyperandrogenism(hirsutism or acne) or hyperandrogenemia(testosterone &gt; 70 ng/ml)
             normal prolactin, TSH, 17-OH progesterone no evidence of androgen producing
             malignancy, Cushing's syndrome or acromegaly age 18-40 reliable use of birth control
             pill for at least 3 months and no plans of pregnancy

        Exclusion Criteria:

          -  elevated creatinine kinase above 2 times upper limit of normal or liver enzymes
             (transaminase) above 2 times of upper limit of normal use of any following
             medications: cyclosporine, fibrates niacin,antifungal agents, macrolide antibiotics
             use of oral contraceptives and other steroid hormones 3 months prior to the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leszek Pawelczyk, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Medical Scienses</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoni J Duleba, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beata E Banaszewska, MD PhD</last_name>
    <phone>+48 618419412</phone>
    <email>bbeata@gpsk.am.poznan.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Z Spaczynski, MD PhD</last_name>
    <phone>+48 618419412</phone>
    <email>rspaczynski@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obstetrics</name>
      <address>
        <city>Poznan</city>
        <zip>60-184</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2006</study_first_posted>
  <last_update_submitted>November 3, 2006</last_update_submitted>
  <last_update_submitted_qc>November 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2006</last_update_posted>
  <keyword>PCOS</keyword>
  <keyword>Statin</keyword>
  <keyword>Metformin</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Menstrual cycle</keyword>
  <keyword>Lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

